VivoSeq
Other

Hematologic Disorder

3

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Hematologic Disorder is an early-stage landscape with 3 programs across 3 companies. The most active players are Akero Therapeutics, Sanofi, UCB.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Akero Therapeutics logo

Akero Therapeutics

1 program

PreclinicalSanofi logo

Sanofi

1 program

PreclinicalUCB logo

UCB

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical3

Busulfan

Akero Therapeutics

Fludarabine

Sanofi

Levetiracetam

UCB

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

75%

Small molecule

3 of 4 classified programs — the dominant modality here.

25%ALL OTHERSCell therapy125%

Small molecule leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 100% of 4 pipeline programs.

Analysis

Trial Status

4

clinical trials

Completed2 · 50%
Recruiting2 · 50%

Clinical Trials

Trial Activity

Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
Completed·—·Phase 2·NCT00636909·25 enrolled
Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders
Completed·UUniversity of British Columbia·N/A·NCT00897260·27 enrolled
ATHN Transcends: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People With Non-Neoplastic Hematologic Disorders
Recruiting·AAmerican Thrombosis and Hemostasis Network·N/A·NCT04398628·3,000 enrolled
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
Recruiting·MMasonic Cancer Center, University of Minnesota·Preclinical·NCT01666080·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)